[Skip to Content]
[Skip to Content Landing]
February 6, 1967


JAMA. 1967;199(6):35-46. doi:10.1001/jama.1967.03120060013004

This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.


Processed Calf Bone, Once Promising, Found To Have `Little Or No Value  'Processed calf bone, widely-reported as the near-equal of fresh autogenous bone in grafts, has little or no value in encouraging new bone growth or preventing ingrowth of fibrous tissue into a bone defect, a group of orthopedic surgeons reports.Kingsbury G. Heiple, MD, told the American Academy of Orthopaedic Surgeons that processed heterogenous calf bone (BOPLANT or SURGIBONE) does not exert any osteogenic effect apart from that evidenced by its recipient bed.

Stockpiles Used  Although Boplant (approved by the Food and Drug Administration several years ago) is no longer being distributed, approval has not been withdrawn. "Presumably," Dr. Heiple said, "there are stockpiles of the material still being used by surgeons."In a recent study undertaken by Dr. Heiple and three colleagues from the division of orthopedic surgery at Western Reserve University School of Medicine, Boplant was judged